Literature DB >> 9708400

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

R M Hoetelmans1, M H Reijers, G J Weverling, R W ten Kate, F W Wit, J W Mulder, H M Weigel, P H Frissen, M Roos, S Jurriaans, H Schuitemaker, F de Wolf, J H Beijnen, J M Lange.   

Abstract

OBJECTIVE: To investigate the relationship between exposure to antiretroviral drugs and the initial decline of plasma HIV-1 RNA.
DESIGN: Open-label study in antiretroviral-naive HIV-1 infected patients using a quadruple drug regimen [nelfinavir (NFV), saquinavir (SQV), stavudine, and lamivudine].
METHODS: The elimination rate constant (k) for HIV-1 clearance was calculated during the first 2 weeks of treatment in 29 patients. Exposure to NFV and SQV was quantified on each study visit. Observed NFV and SQV concentrations were related to those expected in a reference population and a concentration ratio was calculated. The median concentration ratios for NFV and SQV, the baseline CD4+ lymphocyte count and baseline log10 HIV-1 RNA were correlated with k.
RESULTS: A significant positive correlation was observed between k and the median NFV (P = 0.001) or SQV concentration ratio (P = 0.016) in univariate analysis. In multivariate analyses, the median NFV concentration ratio remained significantly correlated with k.
CONCLUSIONS: The variation in the rate of decline of plasma HIV-1 RNA between patients after the initiation of a quadruple drug regimen could be explained by differences in exposure to NFV or SQV. Determination of k could be used to optimise further antiretroviral drug therapy and may be a first tool to assess antiretroviral activities of new or increasing doses of drugs administered in combination regimens. Furthermore, our data suggest that exposure to antiretroviral drugs should be incorporated in mathematical models to describe HIV-1 dynamics in more detail.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708400     DOI: 10.1097/00002030-199811000-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  15 in total

1.  Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors.

Authors:  Peter L. Anderson; Courtney V. Fletcher
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.725

Review 2.  The role of therapeutic drug monitoring in treatment of HIV infection.

Authors:  D J Back; S H Khoo; S E Gibbons; C Merry
Journal:  Br J Clin Pharmacol       Date:  2001-04       Impact factor: 4.335

3.  Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.

Authors:  Y Khaliq; K Gallicano; I Seguin; K Fyke; G Carignan; D Bulman; A Badley; D W Cameron
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 4.  Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis?

Authors:  Offie Porat Soldin; Ronald J Elin; Steven J Soldin
Journal:  Arch Pathol Lab Med       Date:  2003-01       Impact factor: 5.534

5.  The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients.

Authors:  Lisa M Demeter; A Lisa Mukherjee; Robin DiFrancesco; Hongyu Jiang; Robert DiCenzo; Barbara Bastow; Alex R Rinehart; Gene D Morse; Mary Albrecht
Journal:  HIV Clin Trials       Date:  2008 Jan-Feb

Review 6.  Nelfinavir: an update on its use in HIV infection.

Authors:  A Bardsley-Elliot; G L Plosker
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 7.  Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.

Authors:  Peter L Anderson; Courtney V Fletcher
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

8.  Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.

Authors:  Margaret Lartey; Kwamena W Sagoe; Hongmei Yang; Ernest Kenu; Fafa Xexemeku; Joseph Oliver-Commey; Vincent Boima; Markafui Seshie; Augustine Sagoe; Julius A A Mingle; Timothy P Flanigan; Hulin Wu; Awewura Kwara
Journal:  Clin Infect Dis       Date:  2011-01-20       Impact factor: 9.079

9.  The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Authors:  Marta Boffito; Patrick G Hoggard; Helen E Reynolds; Stefano Bonora; E Rhiannon Meaden; Alessandro Sinicco; Giovanni Di Perri; David J Back
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

10.  Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.

Authors:  Déborah Hirt; France Mentré; Agnès Tran; Elisabeth Rey; Solange Auleley; Dominique Salmon; Xavier Duval; Jean-Marc Tréluyer
Journal:  Br J Clin Pharmacol       Date:  2007-10-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.